trimoprostil: RN refers to (5Z,11alpha,13E,15R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917757 |
| CHEMBL ID | 2104498 |
| SCHEMBL ID | 564049 |
| MeSH ID | M0116787 |
| Synonym |
|---|
| ulstar |
| trimoprostil |
| ro-216937 |
| ro-216937/000 |
| prosta-5,13-dien-1-oic acid, 15-hydroxy-11,16,16-trimethyl-9-oxo-, (5z,11alpha,13e,15r)- |
| 15-hydroxy-9-oxo-11,16,16-trimethylprosta-5,13-dien-1-oic acid (5z,11-alpha,13e,15r) |
| (z)-7-((1r,2r,3r)-2-((e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl)-3-methyl-5-oxocyclopentyl)-5-heptenoic acid |
| prosta-5,13-dien-1-oic acid, 15-hydroxy-9-oxo-11,16,16-trimethyl-, (5z,11-alpha,13e,15r)- |
| trimoprostilo [spanish] |
| trimoprostil [usan:inn] |
| trimoprostilum [latin] |
| ro 21-6937 |
| ro-21-6937 |
| ro 21-6937/000 |
| 69900-72-7 |
| D06240 |
| trimoprostil (usan/inn) |
| (z)-7-[(1r,2r,3r)-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-3-methyl-5-oxocyclopentyl]hept-5-enoic acid |
| unii-4dvl1781yc |
| 4dvl1781yc , |
| trimoprostilo |
| trimoprostilum |
| CHEMBL2104498 |
| ro-216937000 |
| trimoprostil [inn] |
| (z)-7-[(1r,2r,3r)-2-[(e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl]-3-methyl-5-oxocyclopentyl]-5-heptenoic acid |
| ro-21-6937/000 |
| prosta-5,13-dien-1-oic acid, 15-hydroxy-11,16,16-trimethyl-9-oxo-, (5z,11.alpha.,13e,15r)- |
| trimoprostil [mart.] |
| trimoprostil [usan] |
| trimoprostil [mi] |
| trimoprostil [jan] |
| SCHEMBL564049 |
| (5z,11alpha,13e,15r)-15-hydroxy-11,16,16-trimethyl-9-oxoprosta-5,13-dien-1-oic acid |
| OOAHNJDZICJECC-BHWPLRMJSA-N |
| (5z,11alpha,13e,15r)-15-hydroxy-11,16,16-trimethyl-9-oxoprosta5,13-dien-1-oic acid |
| AC-31148 |
| Q27259462 |
| DTXSID201021722 |
Trimoprostil is a new synthetic prostaglandin E2 analogue. It inhibits acid secretion and has mucosal protective properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Trimoprostil is a new synthetic prostaglandin E2 analogue that inhibits acid secretion and has mucosal protective properties. " | ( A multicentre comparison of trimoprostil and cimetidine in the treatment of duodenal ulcer. U.K. Trimoprostil Study Collaborative Group. , 1988) | 2.01 |
The influence of food on the bioavailability of trimoprostil, a new antiulcer prostaglandin E2 derivative, was investigated in healthy male volunteers in four separate studies. PGI2 was very poorly absorbed from the intestine, while the absorption of trimorostil was very efficient.
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, PGI2 was very poorly absorbed from the intestine, while the absorption of trimoprostil was very efficient." | ( Biliary, fecal and urinary excretion of [3H]-prostaglandins in the rat. Dashman, T; Gallo-Torres, HE; Kuhn, D; Witt, C, 1987) | 0.5 |
| "The influence of food on the bioavailability of trimoprostil , a new antiulcer prostaglandin E2 derivative, was investigated in healthy male volunteers in four separate studies." | ( Influence of food on the bioavailability of trimoprostil: an overview. Wills, RJ, 1984) | 0.78 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 27 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (41.38%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (58.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||